Table III.
Thrombotic and bleeding complications during long-term observation grouped by type of anticoagulation drug patient received as part of TT. Group 1 patients had a significantly higher rate of PE compared to group 2 patients
| Parameter | Total (n = 136) | Group 1 (n = 77) | Group 2 (n = 57) | Group 3 (n = 2) | χ2 group 1 vs. group 2 | Fisher’s exact test between subgroups, p |
|---|---|---|---|---|---|---|
| Thrombotic complications: | 16 (11.8) | 11 (14.3) | 5 (8.8) | 0 (0) | 0.330 | 0.552 |
| MI | 10 (7.4) | 6 (7.8) | 4 (7.0) | 0 (0) | 0.866 | 0.999 |
| In-stent thrombosis | 7 (5.1) | 5 (6.5) | 2 (3.5) | 0 (0) | 0.443 | 0.729 |
| IS | 1 (0.7) | 0 (0) | 1 (1.8) | 0 (0) | 0.243 | 0.434 |
| PE | 5 (3.7) | 5 (6.5) | 0 (0) | 0 (0) | 0.050 | 0.139 |
| Bleeding: | 45 (33.1) | 28 (36.4) | 17 (29.8) | 0 (0) | 0.428 | 0.519 |
| Major | 14 (10.3) | 10 (13.0) | 4 (7.0) | 0 (0) | 0.246 | 0.512 |
| NMCR | 13 (9.6) | 9 (11.7) | 4 (7.0) | 0 (0) | 0.366 | 0.637 |
| Minor | 32 (23.5) | 18 (23.4) | 14 (24.6) | 0 (0) | 0.874 | 0.999 |
Values are n (%). TT – triple therapy, MI – myocardial infarction, IS – ischemic stroke, PE – peripheral embolism (including mesenteric embolism – pulmonary embolism), NMCR – non-major clinically relevant. Group 1 comprises patients with warfarin/acenocoumarol, group 2 comprises patients with rivaroxaban/dabigatran, group 3 comprises patients with low molecular weight heparin.